Findings {#Sec1}
========

Introduction {#Sec2}
------------

The dopamine (DA) transporter (DAT) tunes DA neurotransmission by active re-uptake of DA from the synapse \[[@CR1]\]. Our laboratory has recently characterized the first *de novo* mutation in the human dopamine transporter (hDAT) reported in a patient diagnosed with autism spectrum disorder (ASD), which results in a Thr to Met substitution at site 356 (hDAT T356M). We reported novel and profound functional abnormalities associated with the hDAT *de novo* mutation T356M, resulting in enhancement of non-vesicular, DAT-dependent DA release, referred to as anomalous DA efflux. Our data raise the possibility that anomalous DA efflux (or other disturbances in DA neurotransmission) may represent a complication relevant for behavioral abnormalities in ASD. Extracellular zinc (Zn^2+^) inhibits DA uptake \[[@CR2]\]. Three amino acid side chains have been identified in DAT which coordinate zinc: H193 in extracellular loop 2 (EL2), H375 in the first helical part of extracellular loop 4 (EL4A), and E396 in the second helix of extracellular loop 4 (EL4B) \[[@CR2],[@CR3]\]. Structural data from the DAT-homolog LeuT in the inward- and outward-facing conformation suggest that the relative orientation of H375 and E396 shifts during the transport cycle \[[@CR4]\].

hDAT T356M displays decreased forward and reverse-transport function compared with wild-type hDAT \[[@CR5]\]. The reduced transport capacity of the mutant was not associated with a reduction in hDAT surface expression. Amphetamine (AMPH) is a psychostimulant that targets the hDAT causing reverse transport of DA (DA efflux) \[[@CR6]\]. hDAT T356M exhibits impaired AMPH-induced DA efflux. Here, we show that the presence of Zn^2+^ partially rescues both DA uptake and the AMPH-induced DA efflux impairments of hDAT T356M. Zn^2+^ diminishes the anomalous DA efflux property of the hDAT T356M, which might account for its ability to partially rescue transporter functions. Rescue of hDAT function by Zn^2+^ might reveal a new molecular mechanism to target for pharmacological intervention in patients with ASD.

Results {#Sec3}
=======

Zn^2+^ enhances \[^3^H\]DA uptake in hDAT T356M {#Sec4}
-----------------------------------------------

CHO cells were transiently transfected with either wild-type hDAT or hDAT T356M. Cells were incubated with 50 nM \[^3^H\]DA at 37 °C for 5 min in the presence of varying concentrations of Zn^2+^. Consistent with previous reports \[[@CR2],[@CR3]\], Zn^2+^ decreases the DA uptake rate for wild-type hDAT (Figure [1](#Fig1){ref-type="fig"}A, filled squares). In contrast, for hDAT T356M cells, Zn^2+^ increases DA uptake, partially reversing the functional deficit of this variant (Figure [1](#Fig1){ref-type="fig"}A, open circles).Figure 1**Zn** ^**2+**^ **partially reverses the hDAT T356M deficits in \[** ^**3**^ **H\]DA uptake and amphetamine (AMPH)-mediated efflux.** Methods were as previously described in Hamilton et al. \[[@CR5]\]. **(A)** \[^3^H\]DA uptake counts (cpm) are plotted for hDAT and hDAT T356M over a range of Zn^2+^ concentrations. While Zn^2+^ inhibits hDAT \[^3^H\]DA uptake, Zn^2+^ instead increases hDAT T356M \[^3^H\]DA uptake (\**p* \< 0.05 by one-way ANOVA followed by Dunnett's test compared to 0 Zn^2+^ control; *n* = 4). **(B)** (*Top)* Representative AMPH-induced amperometric currents (reflecting DA efflux) are displayed in the presence or absence of 100 μM Zn^2+^. Arrows indicate the application of 10 μM AMPH. (*Bottom*) Maximal DA efflux amperometric current recorded in the presence of Zn^2+^ normalized to maximal current recorded in the presence of vehicle. (\**p* \< 0.05 by paired Student's *t*-test; *n* = 5). **(C)** (*Top*) Representative Zn^2+^-induced change in amperometric currents are displayed in response to 100 μM Zn^2+^ or vehicle control. Arrows indicate the application of 100 μM Zn^2+^. (*Bottom*) Change in amperometric current recorded in response to 100 μM Zn^2+^ or vehicle control (\**p* \< 0.05 by paired Student's *t*-test; *n* = 5).

Zn^2+^ enhances AMPH-induced DA efflux in hDAT T356M {#Sec5}
----------------------------------------------------

To specifically measure reverse transport, DA was loaded into the cytoplasm of hDAT T356M cells by a whole-cell patch clamp pipette held in current-clamp mode. This configuration supplies intracellular DA directly to the cell independent of forward transport by hDAT and allows the cell to control its membrane voltage. The whole-cell patch pipette was filled with an internal solution containing 2 mM DA as described previously \[[@CR5]\]. DA efflux in response to 10 μM AMPH was measured by amperometry in the presence of 100 μM Zn^2+^ or vehicle control \[[@CR5]\]. Representative amperometric traces are shown in Figure [1](#Fig1){ref-type="fig"}B (top). The peak of DA efflux normalized to vehicle control is shown in Figure [1](#Fig1){ref-type="fig"}B (bottom). Zn^2+^ increases AMPH-induced DA efflux in hDAT T356M compared to vehicle control (Figure [1](#Fig1){ref-type="fig"}B), indicating an enhancement of reverse transport DA in the presence of Zn^2+^. For comparison, Zn^2+^ partially rescues AMPH-induced DA efflux for hDAT T356M to a level of 48% ± 12% of wild-type hDAT AMPH-induced DA efflux \[[@CR5]\].

Zn^2+^ decreases baseline anomalous DA efflux in hDAT T356M {#Sec6}
-----------------------------------------------------------

Using the whole-cell patch clamp technique coupled to amperometry, the effect of 100 μM Zn^2+^ on the baseline (anomalous) DA efflux of hDAT T356M was studied. The whole-cell patch pipette delivered intracellular DA into the cell in current-clamp mode. To determine the effect of Zn^2+^ on baseline DA efflux, the change in amperometric current was compared following the application of 100 μM Zn^2+^ or vehicle control. Baseline DA efflux decreased significantly in the presence of Zn^2+^ in comparison with that of vehicle, indicating that Zn^2+^ inhibits the constitutive DA efflux by hDAT T356M. Representative amperometric traces are shown in Figure [1](#Fig1){ref-type="fig"}C (top), and mean values are plotted in Figure [1](#Fig1){ref-type="fig"}C (bottom).

Discussion {#Sec7}
==========

Here, we explore the potential for Zn^2+^ in rescuing the biophysical abnormalities in the hDAT variant T356M, which we recently reported in Hamilton et al. \[[@CR5]\]. These functional deficits in hDAT T356M may contribute to the dysfunction in DA neurotransmission associated with ASD. Zn^2+^ was previously shown to partially restore DA uptake function in DAT mutant Y335A, which exhibits low uptake under basal conditions \[[@CR7]\]. Here, we demonstrate that Zn^2+^ reverses deficits in both forward and reverse transport in the T356M variant. Additionally, Zn^2+^ decreases baseline anomalous DA efflux of the hDAT T356M *de novo* mutation, possibly providing an explanation for the positive effects of Zn^2+^ on the uptake and efflux properties of this mutant transporter. This is a novel and intriguing finding in terms of ameliorating irregularities in DAT function in a *de novo* ASD-associated mutation.

T356 is located in transmembrane domain 7, and the hDAT Zn^2+^ binding site spans the spatial micro-environment between the transmembrane helices 7 and 8 and extracellular loop 2 (EL2) \[[@CR8],[@CR9]\]. Binding of Zn^2+^ to DAT alters the conformational equilibrium between the inward- and outward-facing state of the DAT \[[@CR8],[@CR9]\]. However, mutation of an intracellular tyrosine to alanine (Y335A) converts the inhibitory Zn^2+^ switch into an activating Zn^2+^ switch, whereby Zn^2+^ rescues functions of the Y335A mutant transporter \[[@CR7],[@CR8]\]. Therefore, the functional impact of Zn^2+^ binding to mutant transporters can be different than for wild-type hDAT as we observe here for T356M (Figure [1](#Fig1){ref-type="fig"}A). Whereas Zn^2+^ has been suggested to promote the outward facing conformation of wild-type hDAT, the structural effect of Zn^2+^ binding to hDAT T356M is unknown and remains an interesting topic for future investigation.

Clinical data have previously established that mean serum Zn^2+^ levels are significantly lower in children diagnosed with ASD compared to unaffected children and that there exist disturbances in Zn^2+^ metabolism in patients diagnosed with ASD \[[@CR10]-[@CR12]\]. hDAT T356M is the first *de novo* DAT mutation found in a patient with ASD, and hDAT T356M functional deficits can partially be rescued by Zn^2+^. Whether or not Zn^2+^ regulation of hDAT may be directly relevant for the etiology of ASD is presently unknown. However, our work suggests that the molecular mechanism engaged by Zn^2+^ to partially restore function in hDAT T356M may be a novel therapeutic target to rescue, at least in part, functional deficits in hDAT variants associated with ASD.
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